1. Home
  2. SRRK vs AMRX Comparison

SRRK vs AMRX Comparison

Compare SRRK & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation

N/A

Current Price

$42.47

Market Cap

4.6B

Sector

Health Care

ML Signal

N/A

Logo Amneal Pharmaceuticals Inc.

AMRX

Amneal Pharmaceuticals Inc.

N/A

Current Price

$12.05

Market Cap

3.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SRRK
AMRX
Founded
2012
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
3.7B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
SRRK
AMRX
Price
$42.47
$12.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
4
Target Price
$55.40
$14.75
AVG Volume (30 Days)
1.3M
1.9M
Earning Date
03-03-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
157.89
EPS
N/A
0.22
Revenue
N/A
N/A
Revenue This Year
N/A
$6.40
Revenue Next Year
$449.79
$6.54
P/E Ratio
N/A
$53.66
Revenue Growth
N/A
N/A
52 Week Low
$22.71
$6.69
52 Week High
$49.82
$15.42

Technical Indicators

Market Signals
Indicator
SRRK
AMRX
Relative Strength Index (RSI) 45.45 34.79
Support Level $41.54 $11.55
Resistance Level $42.54 $12.12
Average True Range (ATR) 2.40 0.45
MACD 0.05 -0.08
Stochastic Oscillator 38.83 19.21

Price Performance

Historical Comparison
SRRK
AMRX

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Share on Social Networks: